论文部分内容阅读
由中国科学院上海药物研究所新药发现与设计中心承担的国家“863”高技术研究发展计划项目“PPARγ激动剂先导化合物的分子设计”,经过近一年的研究,取得重要进展,现已发现了具有抗糖尿病药理作用的活性化合物70多个。近日,本刊记者走访了该项目负责人沈建华博士。 《医药世界》:请您介绍一下国内外糖尿病药物的研究状况。 沈博士:糖尿病(85％以上是Ⅱ型糖尿病)是一种严重影响人类生命与健康的全球性疾病,根据世界卫生组织(WHO)的调查,2000年全球糖尿病患者为
The “863” high-tech research and development project undertaken by Shanghai Institute of Materia Medica, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, “molecular design of PPARγ agonist lead compounds”, after nearly a year of research and made significant progress has been found More than 70 active compounds have anti-diabetic pharmacological effects. Recently, the reporter visited the project leader Dr. Shen Jianhua. “Pharmaceutical World”: Please tell us about the research status of diabetes drugs at home and abroad. Dr. Shen: Diabetes (more than 85% of type 2 diabetes) is a global disease that seriously affects human life and health. According to the World Health Organization (WHO), the global diabetes in 2000 was